Please use this identifier to cite or link to this item:
http://localhost:80/xmlui/handle/123456789/16457
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yen-An Chen | - |
dc.contributor.author | Hsu, Kuang-Yang | - |
dc.date.accessioned | 2023-01-20T08:06:39Z | - |
dc.date.available | 2023-01-20T08:06:39Z | - |
dc.date.issued | 2014-09-20 | - |
dc.identifier.citation | Chen, Y. A., & Hsu, K. Y. (2014). Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. Pakistan Journal of Pharmaceutical Sciences, 27(5), 1261-1264. | en_US |
dc.identifier.issn | 1011-601X | - |
dc.identifier.uri | http://142.54.178.187:9060/xmlui/handle/123456789/16457 | - |
dc.description.abstract | The aim of presented study was to assess pharmacokinetic properties of fexofenadine in Taiwanese volunteers. Thirty-three healthy male subjects received 180mg fexofenadine. Blood samples were drawn at appropriate times. Drug concentrations of fexofenadine were measured by a LC/MS/MS method. Non-compartmental models were applied to describe the pharmacokinetic characters of fexofenadine. After oral administration of fexofenadine, the Tmax was 1.90±0.81h. The Cmax was 703.76±298.94ng/mL and AUC0-∞ was 4582.52±1812.59h×ng/mL. The elimination half-life of fexofenadine was 12.18±3.61h. One of the most important determinants was to prove the similar results in the pharmacokinetics of fexofenadine in Taiwan subjects compared with the reported data of other ethnic origin. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi. | en_US |
dc.subject | Fexofenadine | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | LC/MS/MS | en_US |
dc.title | Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers | en_US |
dc.type | Article | en_US |
Appears in Collections: | Issue No.5 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Paper-19.htm | 132 B | HTML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.